Leap Therapeutics to Present at Two Investor Conferences in April

CAMBRIDGE, Mass., March 29, 2017 -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President, and Chief Executive Officer, will present corporate overview presentations at the 16^th Annual Needham Healthcare Conference at the Westin New York Grand Central and the 24^th Annual BioCentury Future Leaders In the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. Presentation details for both conferences are summarized below.

The presentation at the 16^th Annual Needham Healthcare Conference will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited time.

Leap Presentation Details:

16^th Annual Needham Healthcare Conference
Date: April 5, 2017
Time: 3:00 P.M. Eastern Time

24^th Future Leaders in the Biotech Industry Conference
Date: April 7, 2017
Time: 9:30 A.M. Eastern Time

About Leap Therapeutics
Leap Therapeutics’ (NASDAQ:LPTX) most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with gastroesophageal cancer in combination with paclitaxel and in patients with biliary tract cancers in combination with gemcitabine and cisplatin. DKN-01 has demonstrated single agent activity in non-small cell lung cancer patients. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response.  For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com/.

FORWARD LOOKING STATEMENTS

Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events of Leap’s development of DKN-01, TRX518, and other programs, future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Leap has attempted to identify forward looking statements by terminology including ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
[email protected]
617-714-0360

Argot Partners

Susan Kim
212-203-4433
[email protected]

or

Heather Savelle
617-663-4863
[email protected]